Damora Therapeutics, Inc. Ordinary Shares DMRA
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $44.20 (+80.2% upside)
Key Stats
- Today's Range
- $23.91 – $25.27
- 50-Day Range
- $23.91 – $34.89
- 52-Week Range
- $16.50 – $34.89
- Volume
- 1.24 million shs
- Average Volume
- 437K shs
- Market Cap
- $1.51 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.69%
- Days to Cover
- 1.94
About Damora Therapeutics, Inc. Ordinary Shares
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Related Stocks
Compare head-to-head: DMRA vs LLY·DMRA vs JNJ·DMRA vs ABBV·DMRA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.